Biotechnology
股价
$117.94
+1.07%市值
$23.33B
今日最高
$119.13
今日最低
$116.70
Incyte Corporation delivered a strong Q1 FY2026, with revenue surging 20.9% YoY to $1.27B and net income nearly doubling to $303.3M, driven by robust product sales and disciplined cost management.
关键风险:High R&D Spending Relative to Revenue
R&D expenses of $515.9M represent approximately 40.5% of Q1 FY2026 revenue, a level that could pressure profitability if pipeline assets fail to advance or receive regulatory approval. Clinical-stage failures could result in significant write-offs with no corresponding revenue benefit.
同属 Biotechnology 行业的其他公司